The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort DOI Creative Commons

Vanelle Larissa Kenmogne,

Mutsa M. Takundwa, Ekene Emmanuel Nweke

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 17, 2025

In South Africa, leukemia remains a major health concern, posing significant challenges in treatment due to its varied subtypes. There is an unmet need for testing pipeline that can identify drug effects on patient samples ex-vivo setting. Using the pilot study with African samples, this paper reports development of drug-sensitivity studying patient-derived cells. Forty-one (41) patients Acute myeloid (AML) (n = 7), Chronic myelogenous (CML) 30), and lymphocytic (CLL) 4) were recruited study. Thirty (30) FDA-approved drugs utilized single sensitivity screening (DSS) cells concentrations (1–1000 nM). The DSS showed distinct pattern different profiles among same subtype, confirming precision therapy. This observed irinotecan, used solid tumour treatment, demonstrated efficacy PBMCs many compared conventional such as nilotinib. For combination studies, ten clinically relevant selected tested based results tests. marks crucial stride towards revolutionizing Africa through innovative ex vivo platform. pioneering initiative forms basis tailored effective options holding promise more personalized treatment. Further exploration validation these findings could significantly contribute cancer medicine efforts Africa.

Язык: Английский

The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort DOI Creative Commons

Vanelle Larissa Kenmogne,

Mutsa M. Takundwa, Ekene Emmanuel Nweke

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Март 17, 2025

In South Africa, leukemia remains a major health concern, posing significant challenges in treatment due to its varied subtypes. There is an unmet need for testing pipeline that can identify drug effects on patient samples ex-vivo setting. Using the pilot study with African samples, this paper reports development of drug-sensitivity studying patient-derived cells. Forty-one (41) patients Acute myeloid (AML) (n = 7), Chronic myelogenous (CML) 30), and lymphocytic (CLL) 4) were recruited study. Thirty (30) FDA-approved drugs utilized single sensitivity screening (DSS) cells concentrations (1–1000 nM). The DSS showed distinct pattern different profiles among same subtype, confirming precision therapy. This observed irinotecan, used solid tumour treatment, demonstrated efficacy PBMCs many compared conventional such as nilotinib. For combination studies, ten clinically relevant selected tested based results tests. marks crucial stride towards revolutionizing Africa through innovative ex vivo platform. pioneering initiative forms basis tailored effective options holding promise more personalized treatment. Further exploration validation these findings could significantly contribute cancer medicine efforts Africa.

Язык: Английский

Процитировано

0